Squarepoint
RGLS

Squarepoint’s Regulus Therapeutics RGLS Stock Holding History

Squarepoint’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-15,980
Closed -$249K – 3618
2021
Q1 		$249K Buy
15,980
+14,967
+1,477% +$222K ﹤0.01% 2551
2020
Q4 		$14K Buy
+1,013
New +$7.44K ﹤0.01% 2845
2017
Q4 		– Sell
-617
Closed -$93K – 2301
2017
Q3 		$93K Buy
617
+247
+67% +$31.1K ﹤0.01% 1520
2017
Q2 		$44K Buy
+370
New +$61.8K ﹤0.01% 1463
2017
Q1 		– Sell
-245
Closed -$66K – 1855
2016
Q4 		$66K Buy
+245
New +$79.6K ﹤0.01% 1678
2016
Q3 		– Sell
-287
Closed -$99K – 1219
2016
Q2 		$99K Buy
+287
New +$206K 0.01% 977

Other funds holding RGLS

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
ACM
Asymmetry Capital Management San Francisco, California $188M AUM 44.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Squarepoint's RGLS Position: Q2 2021 in Review

Squarepoint sold out of Regulus Therapeutics (RGLS) in Q2 2021, closing a stake of 15,980 shares — an estimated $249K sold.

Squarepoint first reported a position in RGLS in Q2 2016 and held it in 6 quarters. The position peaked at $249K in Q1 2021. 44 funds tracked by Wall St. Rank hold RGLS as of Q2 2021.

  • Squarepoint reported no remaining Regulus Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Squarepoint sold 15,980 Regulus Therapeutics shares in Q2 2021, an estimated $249K.
  • Squarepoint first reported a position in Regulus Therapeutics in Q2 2016 and held it in 6 quarters.
  • Squarepoint's Regulus Therapeutics position peaked at $249K in Q1 2021.
  • 44 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2021.

Based on Squarepoint's 13F filing for Q2 2021, filed 16 Aug 2021.